BMS gives back eroded Plavix/Avapro rights to Sanofi
This article was originally published in Scrip
It was good while it lasted, but the products at the heart of the marketing alliance between Bristol-Myers Squibb and Sanofi have now fallen to generic competition, and the firms have revised their long-standing agreement. BMS says the new arrangement will allow it to focus on newer products coming out of its pipeline.
You may also be interested in...
INFOGRAPHIC: In 2019, 10 blockbuster medicines booked combined sales of $92.5bn. This infographic examines those drugs that commanded the greatest revenues globally, and answers some key questions. Which therapeutic areas include the most lucrative blockbusters? Which companies enjoyed their spoils? And which drugs were new to the top 10 last year? It also takes a look at the position of these products on the all-important US market.
Fundraising in the life sciences sector has been booming even as firms in many other industries are struggling to stay in business. Goodwin’s David Mardle is upbeat about the sector’s ongoing prospects – although M&A deals are currently proving tricky to complete.
See how much the CEOs and R&D heads of the world’s biggest pharma companies get paid, and how those companies are performing.